Oxaliplatin in practice
1998

Oxaliplatin in Cancer Treatment

Sample size: 490 publication Evidence: moderate

Author Information

Author(s): J-L Misset

Primary Institution: SMST Hôpital Paul Brousse, Villejuif, France

Hypothesis

Oxaliplatin is effective and safe for treating colorectal and advanced ovarian cancers.

Conclusion

Oxaliplatin is a well-tolerated anticancer drug with a favorable safety profile compared to cisplatin.

Supporting Evidence

  • Oxaliplatin has shown a very good safety profile with low haematotoxicity.
  • More than 2700 cycles of oxaliplatin plus 5-FU were administered in the study.
  • Oxaliplatin was better tolerated than cisplatin in terms of various toxicities.

Takeaway

Oxaliplatin is a medicine that helps treat certain types of cancer and is easier on the body than some other cancer medicines.

Methodology

The study involved a cohort of 490 patients treated with oxaliplatin, either alone or in combination with 5-FU/FA, and compared its safety and efficacy to cisplatin.

Limitations

The study primarily focused on safety and did not provide extensive data on long-term efficacy outcomes.

Participant Demographics

Patients included those with advanced colorectal and ovarian cancers, some heavily pretreated.

Statistical Information

P-Value

0.001

Statistical Significance

p=0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication